Posted by Michael Wonder on 02 Mar 2022
Teva Canada welcomes public drug plan reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the non-insured health benefits program for patients prescribed Ajovy (fremanezumab) for the preventive treatment of migraine in adults
2 March 2022 - Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada.
Teva Canada welcomes the recently announced public formulary coverage for AJOVY® (fremanezumab) by Alberta, Saskatchewan, Québec, Veteran Affairs Canada (VAC) and the Non-Insured Health Benefits (NIHB) Program.1,2,3,4 AJOVY® is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month.
